NEWS
LATEST
FULL LIST
-
OrganOx Secures $160M in Private Financing to Accelerate Organ Perfusion Technology Expansion
Oxford, UK – May 8, 2025 — OrganOx Ltd. has completed the second closing of a $160 million private financing round, bringing in new strategic investors Intuitive Ventures and Terumo Ventures. The investment will support the company’s continued expansion of its metra® perfusion technology, which aims to improve transplant outcomes and organ availability globally. Technology…
-
Collagen-Based 3D Bioprinting Offers Fully Perfusable Gel Based Organ-On-Chips
A team of bioengineers at Carnegie Mellon University has unveiled a new tissue engineering platform. The study, published in Science Advances, introduces CHIPS (Collagen-based High-resolution Internally Perfusable Scaffolds), a new class of biological, perfusable 3D-printed tissue constructs, and VAPOR, a customizable perfusion bioreactor designed to support them. What’s the Technology? The platform uses an improved…
-
Quris Technologies Demonstrates Liver-Driven Brain Toxicity in New Multi-Organ Model
A recent study by Quris Technologies highlights how drug metabolism in the liver can significantly alter a compound’s neurotoxicity, providing new insights into limitations of traditional drug testing methods. Published in Biomedicine & Pharmacotherapy, the findings suggest a greater role for multi-organ, human-relevant testing platforms in preclinical development. Using a proprietary platform called BioAI, Quris…
-
VivoSim Labs Introduces NAMkind Platform for Human-Based Drug Testing Models
VivoSim Labs, a new initiative associated with Organovo, has launched a suite of services under the brand “NAMkind,” aimed at improving drug development through human-based predictive models. The company focuses on New Approach Methodologies (NAMs), which include both engineered human tissue systems and in silico modeling, to offer alternatives to traditional animal testing. VivoSim develops…
-
Cellino and Karis Bio Partner to Advance Personalized iPSC Therapies for Peripheral Artery Disease
Cellino, a Cambridge-based biotech innovator specializing in autonomous biomanufacturing, has announced a strategic partnership with Karis Bio, a South Korean leader in cell therapy, to drive forward a groundbreaking autologous induced pluripotent stem cell (iPSC)-derived therapy for cardiovascular disease. This collaboration not only marks Cellino’s expansion into the Asia-Pacific market but also represents a pivotal…
-
Vivodyne CEO Discusses FDA’s Move Away from Animal Testing and the Future of Humanized Drug Development
By Contract Pharma Staff Vivodyne, a pioneering biotech developing humanized drug testing platforms, stands positioned to capitalize as the FDA announces its initiative to phase out animal testing requirements for monoclonal antibodies (mAbs) and other drug therapies. With its fully automated platform that uses lab-grown human tissues and AI-driven analysis, Vivodyne is ready to push…
-
Organovo Rebrands as VivoSim Labs to Advance 3D Bioprinting Technology
Organovo Holdings, Inc. (Nasdaq: ONVO), a pioneer in 3D bioprinting technology, announced today that it will officially change its name to VivoSim Labs, Inc., marking a new chapter in the company’s mission to advance bioprinting innovations. The rebranding takes effect on April 24, 2025, when the company will begin trading under the new ticker symbol…
-
Cellbricks Reports Preclinical Success with Bioprinted Tissue in Mice
German startup Cellbricks Therapeutics, a spin-off of the Technical University of Berlin, has announced successful preclinical results for its 3D-bioprinted adipose tissue implants. In a study conducted on mice, the company reported full integration of the implants into host tissue after seven weeks, without signs of fibrosis or rejection. Milestone in Animal Testing According to…
-
FluidForm Bio Launches $1.24M Crowdfunding Round to Advance Bioprinted Diabetes Therapy
FluidForm Bio, a regenerative medicine company developing 3D bioprinted cell therapies for diabetes, has launched a new fundraising campaign on StartEngine, aiming to raise up to $1.24 million through a convertible note offering. The Waltham-based company is pursuing a novel approach to treating type 1 diabetes using its proprietary FRESH™ (Freeform Reversible Embedding of Suspended…
-
Xylyx Bio Secures $1.125 Million to Advance Innovations in Xenogeneic Cross-Circulation Transplant Organs
Xylyx Bio, Inc., a regenerative medicine company, today announced that it has received $1,000,000 from the Richard M. Bartlett Jr. Memorial Foundation and an additional $125,000 from the Ilene Beal Foundation and Margaret Stewart Lindsay Foundation. These funds will accelerate the translational development of Xylyx’s groundbreaking bioengineered human lung grafts, which aim to drastically increase…
Subscribe
Enter your email below to receive updates.
The Business of Biofabrication 